Latest Pharma Insights
Deals Shaping The Medtech And Diagnostics Industries, August 2024
An interactive look at medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.
Medtech Insight - September 9, 2024
An interactive look at medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.
Medtech Insight - September 9, 2024
Deals Shaping The Medtech And Diagnostics Industries, July 2024
An interactive look at medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.
Medtech Insight - September 9, 2024
An interactive look at medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.
Medtech Insight - September 9, 2024
AstraZeneca's Hopes Still High For Tozorakimab In COPD
The company's IL-33 drug failed to improve breathing in a chronic obstructive pulmonary disease Phase II trial but benefited patients...
Scrip - September 9, 2024
The company's IL-33 drug failed to improve breathing in a chronic obstructive pulmonary disease Phase II trial but benefited patients...
Scrip - September 9, 2024
Merck & Co and Daiichi’s Phase II ADC Hit Raises Expectations
Ifinatamab deruxtecan, a potential first-in-class B7-H3-targeted conjugate, looks promising – but the real test is to come.
Scrip - September 9, 2024
Ifinatamab deruxtecan, a potential first-in-class B7-H3-targeted conjugate, looks promising – but the real test is to come.
Scrip - September 9, 2024
Global Pharma Guidance Tracker – August 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global...
Pink Sheet - September 9, 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global...
Pink Sheet - September 9, 2024
Pipeline Watch: Seven Approvals And 13 Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies...
Scrip - September 9, 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies...
Scrip - September 9, 2024
EMA Probe Prompts New Safety Measures For Decades-Old Drug Metamizole
The European Medicines Agency’s safety committee has concluded that the benefits of medicines containing metamizole continue to outweigh the risks...
Pink Sheet - September 9, 2024
The European Medicines Agency’s safety committee has concluded that the benefits of medicines containing metamizole continue to outweigh the risks...
Pink Sheet - September 9, 2024
AAM Warns Hikma Case Risks Narrowing Skinny-Label Path To ‘Vanishing Point’
In an amicus brief filed in support of Hikma over its US skinny-label generic dispute with Amarin, local industry association...
Generics Bulletin - September 9, 2024
In an amicus brief filed in support of Hikma over its US skinny-label generic dispute with Amarin, local industry association...
Generics Bulletin - September 9, 2024
Hikma Launches Multiple Concentrations Of Clindamycin In The US
After presenting its interim results for the past six months in August, Hikma has announced a further injectable launch in...
Generics Bulletin - September 9, 2024
After presenting its interim results for the past six months in August, Hikma has announced a further injectable launch in...
Generics Bulletin - September 9, 2024
Apotex Secures Two Firsts With US Sprycel And Oxtellar ER Rivals
After announcing several deals that push Apotex into branded product waters, the Canadian player has announced two landmark first generic...
Generics Bulletin - September 9, 2024
After announcing several deals that push Apotex into branded product waters, the Canadian player has announced two landmark first generic...
Generics Bulletin - September 9, 2024
Slow Progress: A Decade Of Cell Therapy In Japan
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around...
In Vivo - September 9, 2024
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around...
In Vivo - September 9, 2024
Execs On The Move: August 2024
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - September 9, 2024
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - September 9, 2024
China Suspends Dr Reddy’s ADHD Drug Due To ‘Serious Defects’
China’s NMPA import ban on a Dr Reddy’s ADHD drug due to manufacturing issues has left the firm calculating the...
Generics Bulletin - September 9, 2024
China’s NMPA import ban on a Dr Reddy’s ADHD drug due to manufacturing issues has left the firm calculating the...
Generics Bulletin - September 9, 2024
Former Hilleman CEO On Microbiome Project, Cholera, Halal Vaccine
Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former...
Scrip - September 9, 2024
Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former...
Scrip - September 9, 2024
Sandoz Feels It Has The Ingredients To Make A Splash In ADCs
Sandoz’s Strategic Review 2024 event gave the firm the chance to speak at length about its aspirations in the development...
Generics Bulletin - September 9, 2024
Sandoz’s Strategic Review 2024 event gave the firm the chance to speak at length about its aspirations in the development...
Generics Bulletin - September 9, 2024
Akeso/Summit’s Bispecific Ivonescimab Bests Keytruda In 1L NSCLC
Ivonescimab has shown significant and "extremely commercially meaningful" improvements in progression-free survival versus Keytruda as a first-line therapy for lung...
Scrip - September 9, 2024
Ivonescimab has shown significant and "extremely commercially meaningful" improvements in progression-free survival versus Keytruda as a first-line therapy for lung...
Scrip - September 9, 2024
AstraZeneca's Hopes Still High For Tozorakimab In COPD
The company's IL-33 drug failed to improve breathing in a chronic obstructive pulmonary disease Phase II trial but benefited patients...
Scrip - September 9, 2024
The company's IL-33 drug failed to improve breathing in a chronic obstructive pulmonary disease Phase II trial but benefited patients...
Scrip - September 9, 2024
Merck & Co and Daiichi’s Phase II ADC Hit Raises Expectations
Ifinatamab deruxtecan, a potential first-in-class B7-H3-targeted conjugate, looks promising – but the real test is to come.
Scrip - September 9, 2024
Ifinatamab deruxtecan, a potential first-in-class B7-H3-targeted conjugate, looks promising – but the real test is to come.
Scrip - September 9, 2024
Pipeline Watch: Seven Approvals And 13 Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies...
Scrip - September 9, 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies...
Scrip - September 9, 2024
Former Hilleman CEO On Microbiome Project, Cholera, Halal Vaccine
Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former...
Scrip - September 9, 2024
Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former...
Scrip - September 9, 2024
Akeso/Summit’s Bispecific Ivonescimab Bests Keytruda In 1L NSCLC
Ivonescimab has shown significant and "extremely commercially meaningful" improvements in progression-free survival versus Keytruda as a first-line therapy for lung...
Scrip - September 9, 2024
Ivonescimab has shown significant and "extremely commercially meaningful" improvements in progression-free survival versus Keytruda as a first-line therapy for lung...
Scrip - September 9, 2024
Global Pharma Guidance Tracker – August 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global...
Pink Sheet - September 9, 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global...
Pink Sheet - September 9, 2024
EMA Probe Prompts New Safety Measures For Decades-Old Drug Metamizole
The European Medicines Agency’s safety committee has concluded that the benefits of medicines containing metamizole continue to outweigh the risks...
Pink Sheet - September 9, 2024
The European Medicines Agency’s safety committee has concluded that the benefits of medicines containing metamizole continue to outweigh the risks...
Pink Sheet - September 9, 2024
Deals Shaping The Medtech And Diagnostics Industries, August 2024
An interactive look at medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.
Medtech Insight - September 9, 2024
An interactive look at medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.
Medtech Insight - September 9, 2024
Deals Shaping The Medtech And Diagnostics Industries, July 2024
An interactive look at medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.
Medtech Insight - September 9, 2024
An interactive look at medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.
Medtech Insight - September 9, 2024
Longer US FDA Guidance On Nitrosamine Testing Still Short Of OTC Industry’s Requests
“Control of Nitrosamine Impurities in Human Drugs” guidance, FDA’s third on the subject, adds nearly 20 pages to 2021 guidance...
HBW Insight - September 8, 2024
“Control of Nitrosamine Impurities in Human Drugs” guidance, FDA’s third on the subject, adds nearly 20 pages to 2021 guidance...
HBW Insight - September 8, 2024
AAM Warns Hikma Case Risks Narrowing Skinny-Label Path To ‘Vanishing Point’
In an amicus brief filed in support of Hikma over its US skinny-label generic dispute with Amarin, local industry association...
Generics Bulletin - September 9, 2024
In an amicus brief filed in support of Hikma over its US skinny-label generic dispute with Amarin, local industry association...
Generics Bulletin - September 9, 2024
Hikma Launches Multiple Concentrations Of Clindamycin In The US
After presenting its interim results for the past six months in August, Hikma has announced a further injectable launch in...
Generics Bulletin - September 9, 2024
After presenting its interim results for the past six months in August, Hikma has announced a further injectable launch in...
Generics Bulletin - September 9, 2024
Apotex Secures Two Firsts With US Sprycel And Oxtellar ER Rivals
After announcing several deals that push Apotex into branded product waters, the Canadian player has announced two landmark first generic...
Generics Bulletin - September 9, 2024
After announcing several deals that push Apotex into branded product waters, the Canadian player has announced two landmark first generic...
Generics Bulletin - September 9, 2024
China Suspends Dr Reddy’s ADHD Drug Due To ‘Serious Defects’
China’s NMPA import ban on a Dr Reddy’s ADHD drug due to manufacturing issues has left the firm calculating the...
Generics Bulletin - September 9, 2024
China’s NMPA import ban on a Dr Reddy’s ADHD drug due to manufacturing issues has left the firm calculating the...
Generics Bulletin - September 9, 2024
Sandoz Feels It Has The Ingredients To Make A Splash In ADCs
Sandoz’s Strategic Review 2024 event gave the firm the chance to speak at length about its aspirations in the development...
Generics Bulletin - September 9, 2024
Sandoz’s Strategic Review 2024 event gave the firm the chance to speak at length about its aspirations in the development...
Generics Bulletin - September 9, 2024
Slow Progress: A Decade Of Cell Therapy In Japan
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around...
In Vivo - September 9, 2024
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around...
In Vivo - September 9, 2024
Execs On The Move: August 2024
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - September 9, 2024
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - September 9, 2024